|Min SIP Amount||₹1000|
|NAV||₹10.35 (19 Sep 2019)|
|Fund Started||25 Jun 2018|
|Fund Size||₹346 Cr|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||13.7%|
|Divi's Laboratories Ltd.||Healthcare||Equity||10.3%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||7.8%|
|Torrent Pharmaceuticals Ltd.||Healthcare||Equity||7.1%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||5.3%|
|Ipca Laboratories Ltd.||Healthcare||Equity||5.1%|
|Vinati Organics Ltd.||Chemicals||Equity||4.6%|
|Dr. Lal Pathlabs Ltd.||Healthcare||Equity||4.1%|
Mirae Asset Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by Mirae Asset Mutual Fund. This scheme was introduced to investors on 25 Jun 2018. Neelesh Surana is the Current Fund Manager of Mirae Asset Healthcare Fund Direct Growth.The fund currently has an Asset Under Management(AUM) of ₹346 Cr and the Latest NAV as of 19 Sep 2019 is ₹10.35.
The Mirae Asset Healthcare Fund Direct Growth is rated High risk. Minimum SIP Investment is 1000. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year..
1st Floor, Proms Complex, SBI
Colony, 1A Koramangala, 560034